Published in Lancet on June 10, 2006
The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol (2009) 3.40
Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology (2014) 3.36
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol (2008) 2.93
Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review. Neurology (2010) 2.39
Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2010) 2.17
Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace (2013) 1.53
Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord (2015) 1.52
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation (2016) 1.43
Antithrombotic Regimens for Patients Taking Oral Anticoagulation After Coronary Intervention: A Meta-analysis of 16 Clinical Trials and 9,185 Patients. Clin Cardiol (2015) 1.43
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ (2007) 1.29
Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes (2009) 1.29
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc (2013) 1.26
Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence (2010) 1.26
Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol (2012) 1.23
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol (2013) 1.20
Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.15
The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol (2011) 1.14
Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front Neurol (2012) 1.14
Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol (2010) 1.13
Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis. J Gen Intern Med (2013) 1.09
The new oral anticoagulants. Neth Heart J (2010) 1.06
Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology (2012) 1.05
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol (2015) 0.99
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. Neth Heart J (2017) 0.95
Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies. Mayo Clin Proc (2009) 0.93
Anticoagulation in atrial fibrillation. BMJ (2014) 0.93
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. Eur Heart J (2012) 0.93
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS One (2012) 0.93
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J (2013) 0.92
Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J (2014) 0.92
Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. BMJ (2008) 0.91
Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. Medicine (Baltimore) (2015) 0.90
Good old warfarin for stroke prevention in atrial fibrillation. Lancet (2006) 0.90
Weighting components of composite end points in clinical trials: an approach using disability-adjusted life-years. Stroke (2011) 0.89
Trials, registries and guidelines for non-ST-elevation acute coronary syndromes. Neth Heart J (2014) 0.89
Left atrial appendage closure to prevent stroke in patients with atrial fibrillation. Circulation (2014) 0.88
Choices in the use of ICD-9 codes to identify stroke risk factors can affect the apparent population-level risk factor prevalence and distribution of CHADS2 scores. Am J Cardiovasc Dis (2012) 0.88
Antithrombotic medication for cardioembolic stroke prevention. Stroke Res Treat (2011) 0.87
Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis (2012) 0.87
Dabigatran in atrial fibrillation: pharmacology and clinical trials. J Interv Card Electrophysiol (2011) 0.87
Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open (2014) 0.87
Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace (2011) 0.87
Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol (2013) 0.87
The significance of new onset atrial fibrillation complicating acute myocardial infarction. Clin Res Cardiol (2011) 0.86
Stroke prevention in atrial fibrillation: concepts and controversies. Curr Cardiol Rev (2012) 0.86
Incomplete occlusion of the left atrial appendage with the percutaneous left atrial appendage transcatheter occlusion device is not associated with increased risk of stroke. J Interv Card Electrophysiol (2011) 0.86
Treatment of risk factors to prevent stroke. Neurotherapeutics (2011) 0.86
The business case for quality improvement: oral anticoagulation for atrial fibrillation. Circ Cardiovasc Qual Outcomes (2011) 0.86
Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clin Res Cardiol (2009) 0.86
Atrial Fibrillation Ablation without Interruption of Anticoagulation. Cardiol Res Pract (2011) 0.85
Prevention of cardioembolic stroke. Neurotherapeutics (2011) 0.85
Antiplatelet agents for stroke prevention. Neurotherapeutics (2011) 0.85
Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. Eur Heart J (2013) 0.84
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace (2012) 0.84
Current strategies for ischemic stroke prevention: role of multimodal combination therapies. J Neurol (2007) 0.84
Early experience using a left atrial appendage occlusion device in patients with atrial fibrillation. Yonsei Med J (2012) 0.84
Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation. PLoS One (2014) 0.84
Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. J Am Heart Assoc (2016) 0.83
Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels. Methodist Debakey Cardiovasc J (2016) 0.83
Atrial fibrillation and heart failure in the elderly. Heart Fail Rev (2012) 0.83
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation (2012) 0.83
Study protocol: the DESPATCH study: delivering stroke prevention for patients with atrial fibrillation - a cluster randomised controlled trial in primary healthcare. Implement Sci (2011) 0.83
Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation. Am J Med (2014) 0.83
Advancement in antithrombotics for stroke prevention in atrial fibrillation. J Interv Card Electrophysiol (2008) 0.83
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation. Heart Vessels (2013) 0.82
Management of the patient with an acute coronary syndrome using oral anticoagulation. Neth Heart J (2015) 0.82
Stroke Prevention in Atrial Fibrillation: Where are We Now? Clin Med Insights Cardiol (2012) 0.82
The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society. Korean Circ J (2015) 0.82
Anticoagulant therapy for patients with ischaemic stroke. Nat Rev Neurol (2012) 0.82
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag (2013) 0.82
Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb J (2011) 0.82
Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach. Aging Dis (2012) 0.82
Anticoagulation and population risk of stroke and death in incident atrial fibrillation: a population-based cohort study. CMAJ Open (2016) 0.81
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. Am Heart J (2012) 0.81
Systemic Embolic Events (SEE) in Atrial Fibrillation: SEEing Embolic Risk More Clearly. Circulation (2015) 0.81
Evidence-based percutaneous closure of the left atrial appendage in patients with atrial fibrillation. Curr Cardiol Rev (2012) 0.81
Effectiveness and safety of warfarin and anti-platelet drugs for the primary prevention of stroke in patients with non-valvular atrial fibrillation: a meta-analysis. Int J Clin Exp Med (2015) 0.80
Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. J Am Heart Assoc (2016) 0.80
Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm (2012) 0.80
Personalized approach to primary and secondary prevention of ischemic stroke. EPMA J (2014) 0.80
Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clin Pharmacol (2016) 0.80
Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy. Sci Rep (2015) 0.79
Current status of antiplatelet agents to prevent stroke. Curr Neurol Neurosci Rep (2011) 0.79
Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter. Adv Ther (2014) 0.79
Novel anticoagulants in atrial fibrillation stroke prevention. Ther Adv Chronic Dis (2012) 0.79
Current strategies to minimize the bleeding risk of warfarin. J Blood Med (2013) 0.79
Access survival amongst hemodialysis patients referred for preventive angiography and percutaneous transluminal angioplasty. Clin J Am Soc Nephrol (2011) 0.79
Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol (2013) 0.78
Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc (2014) 0.78
Oral anticoagulant therapy and bleeding events with vitamin K antagonists in patients with atrial fibrillation in a Hungarian county hospital. Med Sci Monit (2015) 0.78
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 9.16
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 8.54
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) Lancet (2000) 8.01
Why do we need some large, simple randomized trials? Stat Med (1985) 7.67
An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation (1989) 6.87
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83
Emerging epidemic of cardiovascular disease in developing countries. Circulation (1998) 6.41
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med (1988) 5.81
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
Neuraxial block, death and serious cardiovascular morbidity in the POISE trial. Br J Anaesth (2013) 4.60
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia (2005) 4.45
Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet (1996) 4.28
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med (2000) 4.27
Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA (1993) 4.01
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96
Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet (1998) 3.79
Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet (2002) 3.77
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 3.72
Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J (1996) 3.66
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med (1999) 3.63
Epidemiology and causation of coronary heart disease and stroke in India. Heart (2008) 3.60
Health and peace: time for a new discipline. Lancet (2001) 3.52
Ramipril and the development of diabetes. JAMA (2001) 3.38
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32
Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J (2001) 3.22
Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. CMAJ (1999) 3.18
Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation (2000) 3.12
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ (1996) 2.90
Prevalence of coronary artery disease in Asian Indians. Am J Cardiol (1992) 2.90
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost (2011) 2.87
Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ (1991) 2.81
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation (2007) 2.76
Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev (2002) 2.75
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet (2000) 2.74
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation (1994) 2.61
Increased intraocular pressure and visual field defects in high resistance wind instrument players. Ophthalmology (2000) 2.55
Size and albedo of Kuiper belt object 55636 from a stellar occultation. Nature (2010) 2.49
The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann Intern Med (1995) 2.32
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 2.30
Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ (1989) 2.27
Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed) (1985) 2.27
Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephradine. Antimicrob Agents Chemother (1977) 2.23
Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet (2000) 2.17
Potentially modifiable risk factors associated with myocardial infarction in China: the INTERHEART China study. Heart (2009) 2.16
Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension (2001) 2.15
Intravenous magnesium in acute myocardial infarction. An effective, safe, simple, and inexpensive intervention. Circulation (1993) 2.15
Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology (2008) 2.13
Acute precipitants of congestive heart failure exacerbations. Arch Intern Med (2001) 2.11
Meralgia paraesthetica following open appendicectomy. Ir Med J (2005) 2.06
Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation (2000) 2.05
Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol (2001) 2.05
Cyclical variation of the heart rate in sleep apnoea syndrome. Mechanisms, and usefulness of 24 h electrocardiography as a screening technique. Lancet (1984) 2.04
Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens (2007) 2.01
Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. Lancet (1980) 2.00
Defining the gap between electrographic seizure burden, clinical expression and staff recognition of neonatal seizures. Arch Dis Child Fetal Neonatal Ed (2007) 1.99
Can medicine prevent war? Imaginative thinking shows that it might. BMJ (1999) 1.95
Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol (1991) 1.94
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J (2004) 1.90
Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials (1997) 1.88
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J (2000) 1.88
Stulberg classification system for evaluation of Legg-Calvé-Perthes disease: intra-rater and inter-rater reliability. J Bone Joint Surg Am (1999) 1.85
Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation (1995) 1.85
Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. Antimicrob Agents Chemother (1980) 1.85
Magnesium in acute myocardial infarction. BMJ (1995) 1.80
Depression and risk of sudden cardiac death after acute myocardial infarction: testing for the confounding effects of fatigue. Psychosom Med (2000) 1.80
Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am (1997) 1.79
The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. J Clin Endocrinol Metab (2009) 1.77
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J (1999) 1.76